Previous 10 | Next 10 |
home / stock / mrk / mrk articles
Merck & Co Inc (NYSE: MRK) reported topline data from the Phase 3 KEYNOTE-671 trial investigating Keytruda, Merck's anti-PD-1 therapy,...
CNBC Disney Slashes Children's Ticket Prices Amid Attendance Slump The Walt Disney Company (NYSE: DIS) has unveiled a new series of disco...
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual pri...
ALX Oncology Holdings Inc (NASDAQ: ALXO) released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cy...
Amazon.com, Inc. (NASDAQ:AMZN) is stepping into the generative AI arena with a new product called Bedrock, which offers its Amazon Web Services (AW...
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to particip...
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) released topline results from the KEYNOTE-A39 Phase...
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) have provided updates on two Phase 3 trials, LEAP-006...
HC Wainwright has upgraded Oncternal Therapeutics Inc (NASDAQ: ONCT) to Buy from Neutral with a price target of $2. At the European ...
News, Short Squeeze, Breakout and More Instantly...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the fourth quarter of 2024. Payment will be made on Oct. 7, 2024, to shareholders of r...
2024-07-23 09:30:00 ET The Dow Jones Industrial Average has long been a bellwether for the overall health of the U.S. stock market, tracking 30 large publicly owned companies across various sectors. While the index has seen modest gains in 2024, one of its constituents has been signific...
Clesrovimab met all primary safety and efficacy endpoints Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from its Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab (MK-1654), the company’s investigati...